Investors / filer profile

Ra Capital Management, L.p.

active in 22 companies

Pro
Bought: Pro
Sold: 146
Filings: 22
Companies: 2026-08-24
Last filed

EDGAR · CIK 0001346824 ↗

4 of 8 beat the S&P 500

median +28.4% · S&P 500 +9.2%

8 measured · 3 still running · 1 unmeasured

Money flow · By month

Pro: the money-flow chart and the full record→

Disclosed positions

Estimated from their latest filings — positions may have changed since

Estimated positions from their latest filingsPro →

All filings on record

Every Form 4 transaction we track for this filer


VORVor Biopharma Inc.	Exercise $5.6K · 1,500 sh	2026-08-24	—
SEPNSepterna, Inc.	Sold $31.73M · 746,500 sh	2026-08-12	—
SEPNSepterna, Inc.	Sold $31.73M · 746,500 sh	2026-08-12	—
ARTVArtiva Biotherapeutics, Inc.	Bought $247.7K · 24,944 sh	2026-07-31	—
ARTVArtiva Biotherapeutics, Inc.	Bought $208.0K · 20,824 sh	2026-07-29	—
IKTInhibikase Therapeutics, Inc.	Other — · 18,030,000 sh	2026-07-29	—
ARTVArtiva Biotherapeutics, Inc.	Bought $412.8K · 41,319 sh	2026-07-24	—
HOWLWerewolf Therapeutics, Inc.	Sold $9.7K · 27,695 sh	2026-06-17	—
HOWLWerewolf Therapeutics, Inc.	Sold $136.2K · 389,216 sh	2026-06-17	—
COAGHemab Therapeutics Holdings, Inc.	Bought $1.54M · 61,523 sh	2026-06-16	—

VORExercise

2026-08-24 · Vor Biopharma Inc.

$5.6K

—

SEPNSold

2026-08-12 · Septerna, Inc.

$31.73M

—

SEPNSold

2026-08-12 · Septerna, Inc.

$31.73M

—

ARTVBought

2026-07-31 · Artiva Biotherapeutics, Inc.

$247.7K

—

ARTVBought

2026-07-29 · Artiva Biotherapeutics, Inc.

$208.0K

—

IKTOther

2026-07-29 · Inhibikase Therapeutics, Inc.

18,030,000

—

ARTVBought

2026-07-24 · Artiva Biotherapeutics, Inc.

$412.8K

—

HOWLSold

2026-06-17 · Werewolf Therapeutics, Inc.

$9.7K

—

HOWLSold

2026-06-17 · Werewolf Therapeutics, Inc.

$136.2K

—

COAGBought

2026-06-16 · Hemab Therapeutics Holdings, Inc.

$1.54M

—

Newest 10 of 146 filingsEvery Form 4 on record, with outcomesPro →

Outcomes measure each position — the first buy in a stock and every buy within 182 days — against the closing price ~6 months (120 trading days) later, with the S&P 500 over the same span for context. Pre-scheduled 10b5-1 plan trades are excluded from the record. Positions are estimated from the latest reported post-transaction holdings, split-adjusted, at the latest close. Built from SEC Form 4 filings and market prices — past outcomes, not predictions or advice.